CervoMed (CRVO) Q1 2026 earnings summary

Executive summary

• Focused on developing neflamapimod, an oral small molecule for age-related brain disorders, with lead indication in dementia with Lewy bodies (DLB).

• Completed Phase 2b RewinD-LB Trial for DLB, funded by a $21.3 million NIA grant, with no further grant funding available.

• No products approved or revenue from product sales to date; expects continued operating losses and need for additional capital.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $12.9 million as of March 31, 2026.

• Net loss was $8.0 million for Q1 2026, compared to $4.9 million for Q1 2025.

• Research and development expenses increased to $5.1 million (up 6% year-over-year), and general and administrative expenses rose to $3.0 million (up 25%).

• No grant revenue recognized in Q1 2026, compared to $1.9 million in Q1 2025.

• Accumulated deficit reached $105.7 million as of March 31, 2026.

Outlook and guidance

• Current cash and equivalents are not expected to fund operations for twelve months from the report date, raising substantial doubt about going concern.

• Plans to seek additional financing through equity, debt, or other arrangements; failure to secure funding may require delaying or terminating development activities.

• Expects expenses to increase as clinical development progresses, especially for planned Phase 3 DLB trial.